Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Neoplasms of the CNS

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 168 articles: HTML format

Single Articles

April 2024
1. HANSFORD JR, Das A, McGee RB, Nakano Y, et al
   Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.
   Clin Cancer Res. 2024 Apr 4. doi: 10.1158/1078-0432.CCR-23-4033.
   PubMed     Abstract available
   
   
   
2. LYNCE F, Lin NU
   From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
   Clin Cancer Res. 2024;30:1217-1219.
   PubMed     Abstract available
   
   
   
3. STANISZEWSKA AD, Pilger D, Gill SJ, Jamal K, et al
   Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
   Clin Cancer Res. 2024;30:1338-1351.
   PubMed     Abstract available
   
   
   March 2024
4. CICCONE R, Quintarelli C, Camera A, Pezzella M, et al
   GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
   Clin Cancer Res. 2024 Mar 29. doi: 10.1158/1078-0432.CCR-23-1880.
   PubMed     Abstract available
   
   
   
5. DESAI PB, Karve A, Zawit M, Arora P, et al
   A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
   Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3341.
   PubMed     Abstract available
   
   
   
6. SCHRECK KC, Strowd RE, Nabors LB, Ellingson BM, et al
   Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.
   Clin Cancer Res. 2024 Mar 6. doi: 10.1158/1078-0432.CCR-23-3241.
   PubMed     Abstract available
   
   
   February 2024
7. FANGUSARO J, Avery RA, Fisher MJ, Packer RJ, et al
   Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
   Clin Cancer Res. 2024 Feb 15. doi: 10.1158/1078-0432.CCR-23-3386.
   PubMed     Abstract available
   
   
   
8. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
   Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Response.
   Clin Cancer Res. 2024;30:639.
   PubMed    
   
   
   
9. MANDONNET E
   Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Letter.
   Clin Cancer Res. 2024;30:638.
   PubMed    
   
   
   January 2024
10. ISER F, Hinz F, Hoffmann DC, Grassl N, et al
    Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2907.
    PubMed     Abstract available
    
    
    
11. HABASHY KJ, Dmello C, Chen L, Arrieta VA, et al
    Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2367.
    PubMed     Abstract available
    
    
    
12. LIM-FAT MJ, Iorgulescu JB, Rahman R, Bhave V, et al
    Clinical and genomic predictors of adverse events in newly diagnosed glioblastoma.
    Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3018.
    PubMed     Abstract available
    
    
    
13. MARGOLIN KA
    The Dance Between Tumor Molecular Biology and Antitumor Immune Response.
    Clin Cancer Res. 2024;30:257-259.
    PubMed     Abstract available
    
    
    
14. PETRONEK MS, Monga V, Bodeker KL, Kwofie M, et al
    Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.
    Clin Cancer Res. 2024;30:283-293.
    PubMed     Abstract available
    
    
    
15. HAYASHI T, Tateishi K, Matsuyama S, Iwashita H, et al
    Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
    Clin Cancer Res. 2024;30:116-126.
    PubMed     Abstract available
    
    
    
16. CUI X, Wang Q, Liu X, Kang C, et al
    Levetiracetam: a potent sword against microglia polarization in gliomas.
    Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3322.
    PubMed     Abstract available
    
    
    December 2023
17. GALBO PM, Madsen AT, Liu Y, Peng M, et al
    Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma.
    Clin Cancer Res. 2023 Dec 7. doi: 10.1158/1078-0432.CCR-23-0493.
    PubMed     Abstract available
    
    
    
18. SLOAN AR, Thapliyal M, Lathia JD
    New T-cell therapies for brain metastasis, CD133 in the driver's seat.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-3051.
    PubMed     Abstract available
    
    
    
19. KURZ SC, Zan E, Cordova C, Troxel AB, et al
    Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2533.
    PubMed     Abstract available
    
    
    
20. KAMSON DO, Puri S, Sang Y, Shi MJ, et al
    Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
    Clin Cancer Res. 2023;29:4863-4869.
    PubMed     Abstract available
    
    
    
21. DAS A, Tabori U, Sambira Nahum LC, Collins NB, et al
    Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
    Clin Cancer Res. 2023;29:4770-4783.
    PubMed     Abstract available
    
    
    November 2023
22. NABAVIZADEH A, Bagley SJ
    Exploiting iron metabolism as a therapeutic vulnerability in glioblastoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-3027.
    PubMed     Abstract available
    
    
    
23. ARRIETA VA, Duerinck J, Burdett KB, Habashy KJ, et al
    ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1889.
    PubMed     Abstract available
    
    
    
24. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
    Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma.
    Clin Cancer Res. 2023 Nov 1. doi: 10.1158/1078-0432.CCR-23-1180.
    PubMed     Abstract available
    
    
    October 2023
25. LI J, Hu H, Qin G, Bai F, et al
    Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-2213.
    PubMed     Abstract available
    
    
    
26. GUO X, Qiu W, Li B, Qi Y, et al
    Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0430.
    PubMed     Abstract available
    
    
    
27. GOTTARDO NG, Gajjar A
    Verschlimmbesserung: Craniospinal Radiotherapy is Essential in WNT Medulloblastoma Patients.
    Clin Cancer Res. 2023 Oct 12. doi: 10.1158/1078-0432.CCR-23-2331.
    PubMed     Abstract available
    
    
    
28. KIELISZEK AM, Mobilio D, Upreti D, Bloemberg D, et al
    Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases.
    Clin Cancer Res. 2023 Oct 3. doi: 10.1158/1078-0432.CCR-23-1735.
    PubMed     Abstract available
    
    
    September 2023
29. LUKAS RV, Horbinski C
    Glioma Response to IDH Inhibition: Real-World Experience.
    Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164.
    PubMed     Abstract available
    
    
    
30. JOHNSON M, Bell A, Lauing KL, Ladomersky E, et al
    Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-0834.
    PubMed     Abstract available
    
    
    
31. FERMI V, Warta R, Wollner A, Lotsch C, et al
    Effective reprogramming of patient-derived M2-polarized glioblastoma-associated microglia/macrophages by treatment with GW2580.
    Clin Cancer Res. 2023 Sep 8. doi: 10.1158/1078-0432.CCR-23-0576.
    PubMed     Abstract available
    
    
    August 2023
32. KINSLOW CJ, Rae AI, Taparra K, Kumar P, et al
    MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1295. doi: 10.1158/1078-0432.CCR-23-1295.
    PubMed     Abstract available
    
    
    
33. NAYYAR N, de Sauvage MA, Chuprin J, Sullivan EM, et al
    CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.
    Clin Cancer Res. 2023 Aug 23:CCR-23-0433. doi: 10.1158/1078-0432.CCR-23-0433.
    PubMed     Abstract available
    
    
    
34. BARBATO MI, Nashed J, Bradford D, Ren Y, et al
    FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.
    PubMed     Abstract available
    
    
    
35. TEW BY, Kalfa AJ, Yang Z, Hurth KM, et al
    ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis.
    Clin Cancer Res. 2023 Aug 16:CCR-23-0290. doi: 10.1158/1078-0432.CCR-23-0290.
    PubMed     Abstract available
    
    
    
36. SRINIVASAN ES, Liu Y, Odion RA, Chongsathidkiet P, et al
    Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors.
    Clin Cancer Res. 2023;29:3214-3224.
    PubMed     Abstract available
    
    
    
37. ELLINGSON BM, Hagiwara A, Morris CJ, Cho NS, et al
    Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1235. doi: 10.1158/1078-0432.CCR-23-1235.
    PubMed     Abstract available
    
    
    July 2023
38. COHEN KJ, Munjapara V, Aguilera D, Castellino RC, et al
    A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma.
    Clin Cancer Res. 2023 Jul 27:CCR-23-0348. doi: 10.1158/1078-0432.CCR-23-0348.
    PubMed     Abstract available
    
    
    
39. LAL B, Kulkarni A, McDermott J, Rais R, et al
    Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0673. doi: 10.1158/1078-0432.CCR-23-0673.
    PubMed     Abstract available
    
    
    
40. KESSLER T, Schrimpf D, Doerner L, Hai L, et al
    Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0926. doi: 10.1158/1078-0432.CCR-23-0926.
    PubMed     Abstract available
    
    
    
41. XU Q, Huang K, Meng X, Weng Y, et al
    Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2023 Jul 21:CCR-23-0388. doi: 10.1158/1078-0432.CCR-23-0388.
    PubMed     Abstract available
    
    
    
42. YUAN W, Zhang Q, Gu D, Lu C, et al
    Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages.
    Clin Cancer Res. 2023 Jul 13:CCR-22-3273. doi: 10.1158/1078-0432.CCR-22-3273.
    PubMed     Abstract available
    
    
    June 2023
43. LY KI, Richardson LG, Liu M, Muzikansky A, et al
    Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0203. doi: 10.1158/1078-0432.CCR-23-0203.
    PubMed     Abstract available
    
    
    
44. FOOTE MB, Argiles G, Rousseau B, Segal NH, et al
    Facts and hopes in colorectal cancer immunotherapy.
    Clin Cancer Res. 2023 Jun 16:CCR-22-2176. doi: 10.1158/1078-0432.CCR-22-2176.
    PubMed     Abstract available
    
    
    
45. CHITTIBOINA P, Mandal D, Bugarini A, Asuzu DT, et al
    Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
    Clin Cancer Res. 2023;29:2199-2209.
    PubMed     Abstract available
    
    
    
46. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    PubMed     Abstract available
    
    
    
47. MACK SC, Bertrand KC
    A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
    Clin Cancer Res. 2023 Jun 1:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-0472.
    PubMed     Abstract available
    
    
    May 2023
48. SHI L, Chen H, Chen K, Zhong C, et al
    The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma.
    Clin Cancer Res. 2023 May 30:CCR-22-3971. doi: 10.1158/1078-0432.CCR-22-3971.
    PubMed     Abstract available
    
    
    
49. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
    Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
    Clin Cancer Res. 2023 May 25:OF1-OF5. doi: 10.1158/1078-0432.CCR-23-0009.
    PubMed     Abstract available
    
    
    
50. MACK SC, Bertrand KC
    A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
    Clin Cancer Res. 2023 May 15:CCR-23-0472. doi: 10.1158/1078-0432.CCR-23-0472.
    PubMed     Abstract available
    
    
    
51. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
    Taming Glioblastoma in 'Real Time': Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology".
    Clin Cancer Res. 2023 May 9:CCR-23-0009. doi: 10.1158/1078-0432.CCR-23-0009.
    PubMed     Abstract available
    
    
    April 2023
52. THIESLER H, Gretenkort L, Hoffmeister L, Albers I, et al
    Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients.
    Clin Cancer Res. 2023 Apr 14:CCR-22-1488. doi: 10.1158/1078-0432.CCR-22-1488.
    PubMed     Abstract available
    
    
    
53. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
    Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
    Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
    PubMed     Abstract available
    
    
    February 2023
54. SACHDEV S, Dmello C, Sonabend AM
    Radiosensitization of IDH-mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.
    Clin Cancer Res. 2023 Feb 24:CCR-23-0018. doi: 10.1158/1078-0432.CCR-23-0018.
    PubMed     Abstract available
    
    
    
55. WIJETUNGA NA, Goglia AG, Weinhold N, Berger MF, et al
    Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
    Clin Cancer Res. 2023;29:775-783.
    PubMed     Abstract available
    
    
    
56. BLANDIN AF, Giglio R, Graham MS, Garcia G, et al
    ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.
    Clin Cancer Res. 2023 Feb 13:CCR-21-3521. doi: 10.1158/1078-0432.CCR-21-3521.
    PubMed     Abstract available
    
    
    
57. VON ROEMELING C, Doonan BP, Klippel K, Schultz D, et al
    Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases.
    Clin Cancer Res. 2023 Feb 7:CCR-22-1682. doi: 10.1158/1078-0432.CCR-22-1682.
    PubMed     Abstract available
    
    
    January 2023
58. JENKINS S, Zhang W, Steinberg SM, Nousome D, et al
    Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
    Clin Cancer Res. 2023 Jan 27:CCR-22-0855. doi: 10.1158/1078-0432.CCR-22-0855.
    PubMed     Abstract available
    
    
    
59. CARNEY SV, Banerjee K, Mujeeb A, Zhu B, et al
    Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance.
    Clin Cancer Res. 2023 Jan 24:CCR-22-1896. doi: 10.1158/1078-0432.CCR-22-1896.
    PubMed     Abstract available
    
    
    
60. LIU Y, Chou FJ, Lang F, Zhang M, et al
    Protein kinase B (PKB/AKT) protects IDH-mutated glioma from ferroptosis via Nrf2.
    Clin Cancer Res. 2023 Jan 17:CCR-22-3179. doi: 10.1158/1078-0432.CCR-22-3179.
    PubMed     Abstract available
    
    
    
61. ORZAN F, De Bacco F, Lazzarini E, Crisafulli G, et al
    Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation.
    Clin Cancer Res. 2023 Jan 17:CCR-22-2903. doi: 10.1158/1078-0432.CCR-22-2903.
    PubMed     Abstract available
    
    
    
62. THOMAS RP, Nagpal S, Iv M, Soltys SG, et al
    Correction: Macrophage Exclusion after Radiation Therapy (MERT): A First-in-Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
    Clin Cancer Res. 2023;29:502.
    PubMed    
    
    
    December 2022
63. KANG KD, Bernstock JD, Totsch SK, Gary SE, et al
    Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
    Clin Cancer Res. 2022;28:5419-5430.
    PubMed     Abstract available
    
    
    
64. KITZBERGER C, Spellerberg R, Han Y, Schmohl KA, et al
    Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice.
    Clin Cancer Res. 2022 Dec 14:CCR-22-1433. doi: 10.1158/1078-0432.CCR-22-1433.
    PubMed     Abstract available
    
    
    
65. WILMOTT JS, Tawbi H, Engh JA, Amankulor NM, et al
    Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
    Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581.
    PubMed     Abstract available
    
    
    November 2022
66. FALLAH J, Brave MH, Weinstock C, Mehta GU, et al
    FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
    Clin Cancer Res. 2022;28:4843-4848.
    PubMed     Abstract available
    
    
    October 2022
67. SOFFIETTI R, Pellerino A
    Brain metastasis from HER2-positive breast cancer: an evolving landscape.
    Clin Cancer Res. 2022 Oct 28. pii: 710102. doi: 10.1158/1078-0432.CCR-22-2853.
    PubMed     Abstract available
    
    
    
68. JUNGWIRTH G, Yu T, Liu F, Cao J, et al
    Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.
    Clin Cancer Res. 2022 Oct 25. pii: 710040. doi: 10.1158/1078-0432.CCR-22-2085.
    PubMed     Abstract available
    
    
    
69. KEBIR S, Ullrich V, Berger P, Dobersalske C, et al
    A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma.
    Clin Cancer Res. 2022 Oct 14. pii: 709776. doi: 10.1158/1078-0432.CCR-22-0611.
    PubMed     Abstract available
    
    
    
70. MAIR MJ, Leibetseder A, Heller G, Puhr R, et al
    Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
    Clin Cancer Res. 2022;28:4565-4573.
    PubMed     Abstract available
    
    
    
71. WANG J, Weiss T, Neidert MC, Toussaint NC, et al
    Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma.
    Clin Cancer Res. 2022 Oct 13. pii: 709764. doi: 10.1158/1078-0432.CCR-22-1741.
    PubMed     Abstract available
    
    
    September 2022
72. KABRAJI S, Ni J, Sammons S, Li T, et al
    Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases.
    Clin Cancer Res. 2022 Sep 8. pii: 709125. doi: 10.1158/1078-0432.CCR-22-1138.
    PubMed     Abstract available
    
    
    August 2022
73. MEISTER H, Look T, Roth P, Pascolo S, et al
    Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma.
    Clin Cancer Res. 2022 Aug 29. pii: 708817. doi: 10.1158/1078-0432.CCR-21-4384.
    PubMed     Abstract available
    
    
    
74. OZCAN G, Singh M, Vredenburgh JJ
    Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
    Clin Cancer Res. 2022 Aug 16. pii: 707826. doi: 10.1158/1078-0432.CCR-22-1585.
    PubMed     Abstract available
    
    
    July 2022
75. REMKE M, Ramaswamy V
    WNT medulloblastoma limbo: How low can we go?
    Clin Cancer Res. 2022 Jul 22. pii: 707155. doi: 10.1158/1078-0432.CCR-22-1780.
    PubMed     Abstract available
    
    
    
76. KLINE C, Jain P, Kilburn L, Bonner ER, et al
    Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003.
    Clin Cancer Res. 2022 Jul 19. pii: 707071. doi: 10.1158/1078-0432.CCR-22-0803.
    PubMed     Abstract available
    
    
    
77. BATOOL SM, Muralidharan K, Hsia T, Falotico S, et al
    Highly sensitive EGFRvIII detection in circulating extracellular vesicle RNA of glioma patients.
    Clin Cancer Res. 2022 Jul 18. pii: 707053. doi: 10.1158/1078-0432.CCR-22-0444.
    PubMed     Abstract available
    
    
    
78. MANNING-GEIST BL, Liu YL, Devereaux KA, Da Cruz Paula A, et al
    Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.
    Clin Cancer Res. 2022 Jul 18. pii: 707055. doi: 10.1158/1078-0432.CCR-22-0713.
    PubMed     Abstract available
    
    
    
79. SAULNIER SHOLLER G, Duda DG, Bergendahl G, Ebb D, et al
    A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
    Clin Cancer Res. 2022 Jul 14. pii: 706989. doi: 10.1158/1078-0432.CCR-22-1169.
    PubMed     Abstract available
    
    
    
80. LI F, Bondra KM, Ghilu S, Studebaker A, et al
    Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
    Clin Cancer Res. 2022 Jul 7. pii: 706904. doi: 10.1158/1078-0432.CCR-22-1052.
    PubMed     Abstract available
    
    
    June 2022
81. XU Z, Murad N, Malawsky D, Tao R, et al
    OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
    Clin Cancer Res. 2022 Jun 23:OF1-OF14. doi: 10.1158/1078-0432.CCR-22-0527.
    PubMed     Abstract available
    
    
    
82. LI J, Jiang J, Bao X, Kumar V, et al
    Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.
    Clin Cancer Res. 2022 Jun 21:OF1-OF13. doi: 10.1158/1078-0432.CCR-22-0405.
    PubMed     Abstract available
    
    
    
83. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    PubMed     Abstract available
    
    
    
84. GUPTA T, Pervez S, Dasgupta A, Chatterjee A, et al
    Omission of upfront craniospinal irradiation in patients with low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure.
    Clin Cancer Res. 2022 Jun 2. pii: 699318. doi: 10.1158/1078-0432.CCR-22-0758.
    PubMed     Abstract available
    
    
    
85. CHENG VWT, de Pennington N, Zakaria R, Larkin JR, et al
    VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
    Clin Cancer Res. 2022;28:2385-2396.
    PubMed     Abstract available
    
    
    
86. DRAAISMA K, Tesileanu CMS, de Heer I, Klein M, et al
    Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial.
    Clin Cancer Res. 2022;28:2440-2448.
    PubMed     Abstract available
    
    
    May 2022
87. XU Z, Murad N, Malawsky DS, Tao R, et al
    OLIG2 is a determinant for the relapse of MYC-amplified medulloblastoma.
    Clin Cancer Res. 2022 May 26. pii: 699250. doi: 10.1158/1078-0432.CCR-22-0527.
    PubMed     Abstract available
    
    
    
88. KOMMALAPATI A, Mansfield AS
    Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases.
    Clin Cancer Res. 2022 May 24. pii: 699172. doi: 10.1158/1078-0432.CCR-22-1137.
    PubMed     Abstract available
    
    
    
89. DMELLO C, Sonabend A, Arrieta VA, Zhang DY, et al
    Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.
    Clin Cancer Res. 2022 May 12. pii: 698878. doi: 10.1158/1078-0432.CCR-21-2563.
    PubMed     Abstract available
    
    
    
90. HARAT M, Blok M, Miechowicz I, Wiatrowska I, et al
    Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma.
    Clin Cancer Res. 2022 May 12. pii: 698881. doi: 10.1158/1078-0432.CCR-22-0171.
    PubMed     Abstract available
    
    
    
91. KUMAR A, Mohamed E, Tong S, Chen K, et al
    CXCL14 promotes a robust brain tumor-associated immune response in glioma.
    Clin Cancer Res. 2022 May 5. pii: 696303. doi: 10.1158/1078-0432.CCR-21-2830.
    PubMed     Abstract available
    
    
    
92. ARAGON-SANABRIA V, Aditya A, Zhang L, Chen F, et al
    Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma.
    Clin Cancer Res. 2022 May 2. pii: 696260. doi: 10.1158/1078-0432.CCR-21-4053.
    PubMed     Abstract available
    
    
    April 2022
93. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.
    Clin Cancer Res. 2022;28:1737.
    PubMed    
    
    
    
94. SABARI JK, Velcheti V, Shimizu K, Strickland MR, et al
    Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2022 Apr 11. pii: 694212. doi: 10.1158/1078-0432.CCR-22-0383.
    PubMed     Abstract available
    
    
    
95. NAYAK L, Standifer N, Dietrich J, Clarke JL, et al
    Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
    Clin Cancer Res. 2022 Apr 8. pii: 694327. doi: 10.1158/1078-0432.CCR-21-4064.
    PubMed     Abstract available
    
    
    
96. YURCHENKO AA, Pop OT, Ighilahriz M, Padioleau I, et al
    Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
    Clin Cancer Res. 2022;28:1422-1432.
    PubMed     Abstract available
    
    
    March 2022
97. SASAME J, Ikegaya N, Kawazu M, Natsumeda M, et al
    HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.
    Clin Cancer Res. 2022 Mar 28. pii: 694027. doi: 10.1158/1078-0432.CCR-21-3622.
    PubMed     Abstract available
    
    
    
98. MADHAVAN K, Balakrishnan I, Lakshmanachetty S, Pierce A, et al
    Venetoclax cooperates with ionizing radiation to attenuate Diffuse Midline Glioma tumor growth.
    Clin Cancer Res. 2022 Mar 28. pii: 694029. doi: 10.1158/1078-0432.CCR-21-4002.
    PubMed     Abstract available
    
    
    
99. LASSMAN AB, Sepulveda-Sanchez JM, Cloughesy T, Gil-Gil MJ, et al
    Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
    Clin Cancer Res. 2022 Mar 28. pii: 688116. doi: 10.1158/1078-0432.CCR-21-2664.
    PubMed     Abstract available
    
    
    
100. NGUYEN TTT, Shang E, Schiffgens S, Torrini C, et al
     Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
     Clin Cancer Res. 2022 Mar 17:OF1-OF15. doi: 10.1158/1078-0432.CCR-21-2857.
     PubMed     Abstract available
     
     
     
101. LE X, Sakai H, Felip E, Veillon R, et al
     Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
     Clin Cancer Res. 2022;28:1117-1126.
     PubMed     Abstract available
     
     
     
102. TESILEANU CMS, Sanson M, Wick W, Brandes AA, et al
     Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial.
     Clin Cancer Res. 2022 Mar 11. pii: 682153. doi: 10.1158/1078-0432.CCR-21-4283.
     PubMed     Abstract available
     
     
     
103. WEI S, Yin D, Yu S, Lin X, et al
     Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.
     Clin Cancer Res. 2022 Mar 4. pii: 682043. doi: 10.1158/1078-0432.CCR-21-0833.
     PubMed     Abstract available
     
     
     February 2022
104. VAN LINDE ME, Labots M, Brahm CG, Hovinga KE, et al
     Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly-diagnosed glioblastoma.
     Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-1933.
     PubMed     Abstract available
     
     
     
105. VAN LINDE ME, Labots M, Brahm CG, Hovinga KE, et al
     Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly-diagnosed glioblastoma.
     Clin Cancer Res. 2022 Feb 14. pii: 681709. doi: 10.1158/1078-0432.CCR-21-1933.
     PubMed     Abstract available
     
     
     
106. XU J, Wu PJ, Lai TH, Sharma P, et al
     Disruption of DNA Repair and Survival Pathways through Heat Shock Protein inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation therapy.
     Clin Cancer Res. 2022 Feb 9. pii: 1078-0432.CCR-20-0468.
     PubMed     Abstract available
     
     
     
107. MILLER KE, Cassady KA, Roth JC, Clements J, et al
     Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
     Clin Cancer Res. 2022;28:498-506.
     PubMed     Abstract available
     
     
     January 2022
108. CHOW LQM, Barlesi F, Bertino EM, van den Bent MJ, et al
     ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
     Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-1838.
     PubMed     Abstract available
     
     
     
109. CAMPIAN JL, Ghosh S, Kapoor V, Yan R, et al
     Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8(+) T cells and enhances survival in mouse glioma models.
     Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-0947.
     PubMed     Abstract available
     
     
     December 2021
110. FITZPATRICK A, Iravani M, Mills A, Childs L, et al
     Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.
     Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3017.
     PubMed     Abstract available
     
     
     
111. GRAHAM LS, Pritchard CC, Schweizer MT
     Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
     Clin Cancer Res. 2021;27:6662-6665.
     PubMed     Abstract available
     
     
     
112. HU JL, Omofoye OA, Rudnick JD, Kim S, et al
     A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
     Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-2867.
     PubMed     Abstract available
     
     
     November 2021
113. KILIAN M, Friedrich M, Sanghvi K, Green E, et al
     T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas.
     Clin Cancer Res. 2021 Nov 15. pii: 1078-0432.CCR-21-1881.
     PubMed     Abstract available
     
     
     
114. LASSMAN AB, Wen PY, van den Bent MJ, Plotkin SR, et al
     A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
     Clin Cancer Res. 2021 Nov 2. pii: 1078-0432.CCR-21-2225.
     PubMed     Abstract available
     
     
     October 2021
115. MEHTA S, Fiorelli R, Bao X, Pennington-Krygier C, et al
     A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
     Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-1096.
     PubMed     Abstract available
     
     
     
116. DELAIDELLI A, Dunham C, Santi M, Negri GL, et al
     Clinically Tractable Outcome Prediction of non-WNT/non-SHH Medulloblastoma Based on TPD52 Immunohistochemistry in a Multicohort Study.
     Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-2057.
     PubMed     Abstract available
     
     
     
117. FURTNER J, Weller M, Weber M, Gorlia T, et al
     Temporal muscle thickness as a prognostic marker in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials.
     Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-1987.
     PubMed     Abstract available
     
     
     September 2021
118. YU S, Wei S, Savani M, Lin X, et al
     A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas.
     Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-0374.
     PubMed     Abstract available
     
     
     
119. SINGH K, Batich KA, Wen PY, Tan AC, et al
     Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
     Clin Cancer Res. 2021 Sep 24. pii: 1078-0432.CCR-21-2681.
     PubMed     Abstract available
     
     
     
120. BAGLEY SJ, Kothari S, Rahman R, Lee EQ, et al
     Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
     Clin Cancer Res. 2021 Sep 24. pii: 1078-0432.CCR-21-2750.
     PubMed     Abstract available
     
     
     
121. NOBASHI TW, Mayer AT, Xiao Z, Chan CT, et al
     Whole-body PET imaging of T cell response to Glioblastoma.
     Clin Cancer Res. 2021 Sep 21. pii: 1078-0432.CCR-21-1412.
     PubMed     Abstract available
     
     
     
122. MARQUEZ-ORTIZ RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, et al
     IL13Ralpha2 promotes proliferation and outgrowth of breast cancer brain metastases.
     Clin Cancer Res. 2021 Sep 20. pii: 1078-0432.CCR-21-0361.
     PubMed     Abstract available
     
     
     
123. ZHAI L, Bell A, Ladomersky E, Lauing KL, et al
     Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma.
     Clin Cancer Res. 2021 Sep 3. pii: 1078-0432.CCR-21-1392.
     PubMed     Abstract available
     
     
     
124. BEINAT C, Patel CB, Haywood T, Murty S, et al
     A Clinical PET Imaging Tracer ([(18)F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.
     Clin Cancer Res. 2021 Sep 2. pii: 1078-0432.CCR-21-0544.
     PubMed     Abstract available
     
     
     August 2021
125. SCHRECK KC, Morin A, Zhao G, Allen AN, et al
     Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF V600E mutant human glioma.
     Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-2660.
     PubMed     Abstract available
     
     
     
126. BOUDREAU CE, Najem H, Ott M, Horbinski C, et al
     INTRATUMORAL DELIVERY OF STING AGONIST RESULTS IN CLINICAL RESPONSES IN CANINE GLIOBLASTOMA.
     Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-1914.
     PubMed     Abstract available
     
     
     
127. GONZALEZ-BUENDIA E, Zhao J, Wang L, Mukherjee S, et al
     TOP2B enzymatic activity on promoters and introns modulates multiple oncogenes in human gliomas.
     Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-0312.
     PubMed     Abstract available
     
     
     
128. SUBBIAH V, Gainor JF, Oxnard GR, Tan DSW, et al
     Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
     Clin Cancer Res. 2021;27:4160-4167.
     PubMed     Abstract available
     
     
     June 2021
129. WU J, Yuan Y, Long Priel DA, Fink D, et al
     Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
     Clin Cancer Res. 2021;27:3298-3306.
     PubMed     Abstract available
     
     
     
130. ANWAR M, Chen Q, Ouyang D, Wang S, et al
     Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
     Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0474.
     PubMed     Abstract available
     
     
     
131. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
     Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases.
     Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-1046.
     PubMed     Abstract available
     
     
     
132. WU AML, Gossa S, Samala R, Chung MA, et al
     Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis.
     Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1549.
     PubMed     Abstract available
     
     
     
133. MELLINGHOFF IK, Penas-Prado M, Peters KB, Burris HA, et al
     Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial.
     Clin Cancer Res. 2021 Jun 2. pii: 1078-0432.CCR-21-0611.
     PubMed     Abstract available
     
     
     May 2021
134. SMALLEY I, Chen Z, Phadke MS, Li J, et al
     Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases.
     Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-1694.
     PubMed     Abstract available
     
     
     
135. SABBAGH A, Beccaria K, Ling X, Marisetty A, et al
     Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models.
     Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-3760.
     PubMed     Abstract available
     
     
     
136. KITAGAWA Y, Tanaka S, Kamiya M, Kuriki Y, et al
     A Novel Topical Fluorescent Probe for Detection of Glioblastoma.
     Clin Cancer Res. 2021 May 23. pii: 1078-0432.CCR-20-4518.
     PubMed     Abstract available
     
     
     
137. WERNER JM, Weller J, Ceccon G, Schaub C, et al
     Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET PET.
     Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-21-0471.
     PubMed     Abstract available
     
     
     April 2021
138. ELLINGSON BM, Sampson JH, Achrol AS, Aghi MK, et al
     Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma.
     Clin Cancer Res. 2021 Apr 16. pii: 1078-0432.CCR-21-0446.
     PubMed     Abstract available
     
     
     March 2021
139. GARCIA-MOURE M, Gonzalez-Huarriz M, Labiano S, Guruceaga E, et al
     Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
     Clin Cancer Res. 2021;27:1807-1820.
     PubMed     Abstract available
     
     
     
140. TOLANEY SM, Sahebjam S, Rhun EL, Bachelot T, et al
     Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
     Clin Cancer Res. 2021;27:1582.
     PubMed    
     
     
     February 2021
141. DEWIRE MD, Fuller C, Campagne O, Lin T, et al
     A Phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: a Pediatric Brain Tumor Consortium Study.
     Clin Cancer Res. 2021 Feb 5. pii: 1078-0432.CCR-20-4078.
     PubMed     Abstract available
     
     
     
142. OTVOS B, Alban TJ, Grabowski MM, Bayik D, et al
     Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome.
     Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3262.
     PubMed     Abstract available
     
     
     
143. BASHIR A, Larsen VA, Ziebell M, Fugleholm K, et al
     Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph (HRRT) PET scanner.
     Clin Cancer Res. 2021 Feb 1. pii: 1078-0432.CCR-20-3362.
     PubMed     Abstract available
     
     
     January 2021
144. ANGUS L, Deger T, Jager A, Martens JWM, et al
     Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases.
     Clin Cancer Res. 2021 Jan 29. pii: 1078-0432.CCR-20-3954.
     PubMed     Abstract available
     
     
     
145. ANDREWS DW, Judy K, Scott CB, Garcia S, et al
     Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.
     Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3805.
     PubMed     Abstract available
     
     
     
146. NAGLE VL, Henry KE, Hertz CAJ, Graham MS, et al
     Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [(64)Cu]Cu-NOTA-anti-CD8-Positron Emission Tomography.
     Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-3243.
     PubMed     Abstract available
     
     
     
147. WAITKUS MS, Yan H
     Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
     Clin Cancer Res. 2021;27:383-388.
     PubMed     Abstract available
     
     
     
148. COLCLOUGH N, Chen K, Johnstrom P, Strittmatter N, et al
     Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
     Clin Cancer Res. 2021;27:189-201.
     PubMed     Abstract available
     
     
     December 2020
149. SEIDLITZ A, Beuthien-Baumann B, Lock S, Jentsch C, et al
     Final results of the prospective biomarker trial PETra: [(11)C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma.
     Clin Cancer Res. 2020 Dec 29. pii: 1078-0432.CCR-20-1775.
     PubMed     Abstract available
     
     
     
150. STADLBAUER A, Kinfe TM, Eyupoglu I, Zimmermann M, et al
     Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans.
     Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3580.
     PubMed     Abstract available
     
     
     
151. CHASTKOFSKY MI, Pituch KC, Katagi H, Zannikou M, et al
     Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
     Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-1499.
     PubMed     Abstract available
     
     
     November 2020
152. KIYOKAWA J, Kawamura Y, Ghouse SM, Acar S, et al
     Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma.
     Clin Cancer Res. 2020 Nov 30. pii: 1078-0432.CCR-20-2400.
     PubMed     Abstract available
     
     
     
153. IORGULESCU JB, Gokhale PC, Speranza MC, Eschle BK, et al
     Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
     Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-2291.
     PubMed     Abstract available
     
     
     
154. NAYAK L, Molinaro AM, Peters KB, Clarke JL, et al
     Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients.
     Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-2500.
     PubMed     Abstract available
     
     
     
155. VIGNESWARAN K, Boyd NH, Oh SY, Lallani S, et al
     YAP/TAZ transcriptional co-activators create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma.
     Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-0018.
     PubMed     Abstract available
     
     
     October 2020
156. ESTEVE-CODINA A, Alameda F, Carrato C, Pineda E, et al
     RNA-Sequencing and immunohistochemistry reveal ZFN7 as a stronger marker of survival than molecular subtypes in G-CIMP-negative glioblastoma.
     Clin Cancer Res. 2020 Oct 26. pii: 1078-0432.CCR-20-2141.
     PubMed     Abstract available
     
     
     
157. BRUZEK AK, Ravi K, Muruganand A, Wadden J, et al
     Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.
     Clin Cancer Res. 2020 Oct 21. pii: 1078-0432.CCR-20-2066.
     PubMed     Abstract available
     
     
     
158. MONTAY-GRUEL P, Acharya MM, Goncalves Jorge P, Petit B, et al
     Hypo-fractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice.
     Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-0894.
     PubMed     Abstract available
     
     
     
159. MURALIDHARAN K, Yekula A, Small JL, Rosh ZS, et al
     TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas.
     Clin Cancer Res. 2020 Oct 13. pii: 1078-0432.CCR-20-3083.
     PubMed     Abstract available
     
     
     
160. PARK JE, Kim HS, Kim N, Park SY, et al
     Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Are Associated with Patient Outcomes in IDH-wildtype Glioblastoma.
     Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2156.
     PubMed     Abstract available
     
     
     September 2020
161. CARRATO C, Alameda F, Esteve-Codina A, Pineda E, et al
     Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy.
     Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-2171.
     PubMed     Abstract available
     
     
     August 2020
162. XING L, Pan Y, Shi Y, Shu Y, et al
     Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study.
     Clin Cancer Res. 2020 Aug 17. pii: 1078-0432.CCR-20-2081.
     PubMed     Abstract available
     
     
     July 2020
163. GOERIG NL, Frey B, Korn K, Fleckenstein B, et al
     Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy.
     Clin Cancer Res. 2020;26:3259-3270.
     PubMed     Abstract available
     
     
     April 2020
164. YUN MR, Kim DH, Kim SY, Joo HS, et al
     Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-2777.
     PubMed     Abstract available
     
     
     March 2020
165. COLE KA, Pal S, Kudgus RA, Ijaz H, et al
     Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
     Clin Cancer Res. 2020;26:1213-1219.
     PubMed     Abstract available
     
     
     
166. KEMENY HR, Elsamadicy AA, Farber SH, Champion CD, et al
     Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
     Clin Cancer Res. 2020;26:1141-1151.
     PubMed     Abstract available
     
     
     February 2020
167. VAZQUEZ-BORREGO MC, Gupta V, Ibanez-Costa A, Gahete MD, et al
     A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.
     Clin Cancer Res. 2020;26:957-969.
     PubMed     Abstract available
     
     
     April 2019
168. COHEN JV, Sullivan RJ
     Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.
     Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-0836.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.